Skip to main content
. 2020 Nov 5;25(21):5148. doi: 10.3390/molecules25215148

Figure 6.

Figure 6

The relative mRNA expression of SMAD2 and SMAD3 after the treatment with 17.7 µg/mL rCTII in the SK-MEL-3 cell line (A,B). The expression level of miR-214 after the treatment with rCTII (C). The expression of candidate genes was assessed through real-time PCR in the control and treated group. Our result demonstrated that for the rCTII protein, the SMAD2 and SMAD3 expression levels were evaluated in the treated and untreated cell line to investigate the rCTII effect on the transforming growth factor-beta (TGF-β) signaling pathway. After melanoma cells were treated with rCTII, there was a significant down-regulation in the expression level of SMAD2 and SMAD3 compared to untreated melanoma cells (both p < 0.01). Subsequent to cancerous cells being treated with rCTII, there was a significant reduction in the expression level of miR-214 compared to untreated melanoma cells (p < 0.05). Error bars display the ± SD. The independent t-tests assessed the p-values. p < 0.05 (*), p < 0.01 (**).